Latest Breaking News On - Condensed interim financial - Page 6 : comparemela.com

Investegate |Vietnam Enterprise Announcements | Vietnam Enterprise: Half-year Report

Investegate |Vietnam Enterprise Announcements | Vietnam Enterprise: Half-year Report
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Hong kongUnited kingdomRepublic ofCity ofKinh bacCayman islandsHo chi minh cityH chíinhBruxelles capitaleVietnam generalHai phongHi phòvmStanley chouDominic scrivenNguyen thanh nghiVi peterson

Pershing Square Holdings, Ltd : Pershing Square Holdings Ltd Releases 2021 Semiannual Financial Statements

Regulatory News: Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (NA:PSH) (the "Company") today released its Semiannual Financial Statements which includes the Investment Manager's Report to Shareholders.

New yorkUnited statesUnited kingdomBailiwick of guernseyGuernsey generalCity ofCayman islandsNoord hollandChannel islandsFreddie macRupert morleyTim hortonPershing squareMike mcmullenRichard wohankaBronwyn curtis

Novartis Pharma AG: Novartis delivered strong Q2 performance, driven by momentum of key growth brands FY 2021 guidance unchanged

Novartis Pharma AG: Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged. Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Oncology BU grew +7% (cc, +11% USD) driven by Promacta/Revolade (+18% cc), Sandoz grew +5% (cc, +11% USD) as the business is starting to stabilize Excluding prior year forward purchasing de-stocking, we estimate Q2 net sales grew +5% (cc, +10% USD), Innovative Medicines grew +7% (cc, +11% USD) and Sandoz declined -1% (cc, + 6% USD)² Q2 core¹ operating income grew +13% (cc, +18% USD) mainly driven by higher sales and favorable gross margin, partly offset by higher spend. Excluding prior year COVID-19 related forward purchasing de-stocking, we estimate core operating income increased +4% (cc, +10% USD)

United statesNew zealandGleevec glivecPromacta revoladeAfinitor votubiaExjade jadenuMoody investors serviceNovartis groupEuropean hematology associationDiovan groupSwiss exchangeUltibro groupExforge groupExchange commissionChinese national medical products administrationEuropean academy for neurology congress

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth Group guidance for FY 2021 confirmed

COVID-19 update The COVID-19 situation continues to evolve and is taking differing courses across the multitude of geographies in which Novartis operates. We continue to take strong actions to help address the pandemic. Our primary concerns remain the health and safety of our associates and patients. There continues to be COVID-19 related lockdowns and disruptions in several geographies negatively impacting demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. For Sandoz, COVID-19 resulted in a historically weak cough and cold season and softened retail demand. At present, drug development operations are continuing with manageable disruptions (see the Innovation Review Section of the Condensed Interim Financial Report for further information), with our range of digital technologies allowing us to proactively manage our clinical trials portfolio and rapidly mitigate any disruptions. Our operations remain stable and cash col

United statesNew zealandGleevec glivecPromacta revoladeAfinitor votubiaExjade jadenuMuscular dystrophy associationMoody investors serviceAmerican college of cardiologyEuropean commissionDiovan groupSwiss exchangeExforge groupAmerican academy of neurologyGalvus groupSandoz retail

Novartis Pharma AG: Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth Group guidance for FY 2021 confirmed

Novartis Pharma AG: Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth Group guidance for FY 2021 confirmed
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNew zealandGleevec glivecPromacta revoladeAfinitor votubiaExjade jadenuMuscular dystrophy associationMoody investors serviceNovartis groupAmerican college of cardiologyEuropean commissionDiovan groupSwiss exchangeExchange commissionExforge groupAmerican academy of neurology